Takeda granted Priority Review for oveporexton by FDA

Takeda (TAK) announced that the FDA accepted its new drug application and granted Priority Review for oveporexton for the treatment of narcolepsy type 1. Oveporexton is an investigational oral orexin receptor 2-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1.